Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07397611 · ClinicalTrials.gov registry record · Phase 2
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
A Phase 2 study of Renal Cell Carcinoma and Kidney Cancer, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 3
- Study locations
NCT07397611: Recruiting Phase 2 study of Renal Cell Carcinoma and Kidney Cancer, sponsored by Dana-Farber Cancer Institute.
NCT07397611 is a Phase 2 study of Renal Cell Carcinoma and Kidney Cancer that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 32 participants, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (87% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07397611, a Phase 2 study of Renal Cell Carcinoma and Kidney Cancer, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to see whether the drug casdatifan is safe and effective either by itself or in combination with the drug zimberelimab in participants with resectable clear cell renal cell carcinoma (ccRCC). The names of the study drugs involved in this study are: * Casdatifan (a type of HIF-2α inhibitor) * Zimberelimab (a type of monoclonal antibody)
Primary Outcome
Tumor size reduction rate is defined as the proportion of participants who achieve any decrease in the maximal dimension of the primary tumor.
Conditions Studied
Interventions
- DRUG Zimberelimab
- DRUG Casdatifan
Study Locations (3)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Brigham and Women's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2026-03-09 |
| Est. Completion | 2029-09-30 |
| Phase | Phase 2 |
What NCT07397611 shows while recruiting
NCT07397611 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (87% lower).
The record links to 4 conditions, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Zimberelimab is the first listed.
NCT07397611 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07397611 about?
NCT07397611 is a clinical study titled "Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC". The purpose of this study is to see whether the drug casdatifan is safe and effective either by itself or in combination with the drug zimberelimab in participants with resectable clear cell renal cell carcinoma (ccRCC). The names of the study drugs involved in this study are: * Casdatifan (a type...
What is the current status of trial NCT07397611?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2026-03-09. Estimated completion is 2029-09-30.
What conditions does trial NCT07397611 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasm, Renal Carcinoma.
What interventions are being tested in trial NCT07397611?
The interventions under investigation include: Zimberelimab (DRUG), Casdatifan (DRUG).
Who is sponsoring clinical trial NCT07397611?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07397611 being conducted?
This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07397611's enrollment target sits among peer trials
32 90th of 121 higher than 30 of 121 other Renal Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)
RECRUITING · Phase 2
-
Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation
RECRUITING · Phase 2
-
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
RECRUITING · Phase 2
-
Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)
RECRUITING · Phase 2
-
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 2
-
A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI